يعرض 601 - 620 نتائج من 21,342 نتيجة بحث عن '(( significant ((all decrease) OR (small decrease)) ) OR ( significant decrease decrease ))', وقت الاستعلام: 0.59s تنقيح النتائج
  1. 601
  2. 602
  3. 603

    Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i> حسب Razia Rashid Rahil (22772495)

    منشور في 2025
    "…(B, C) Summarized bar graph showed EVO significantly decreased calcium deposition and calcium content in CER treated P<sub>i</sub>-induced VSMCs. …"
  4. 604

    Grade system. حسب Zhuoyang Xia (21354186)

    منشور في 2025
    الموضوعات:
  5. 605

    Literature search. حسب Zhuoyang Xia (21354186)

    منشور في 2025
    الموضوعات:
  6. 606

    Study characteristics. حسب Zhuoyang Xia (21354186)

    منشور في 2025
    الموضوعات:
  7. 607

    Flowchart of literature retrieval. حسب Zhuoyang Xia (21354186)

    منشور في 2025
    الموضوعات:
  8. 608

    Data extraction. حسب Zhuoyang Xia (21354186)

    منشور في 2025
    الموضوعات:
  9. 609
  10. 610
  11. 611
  12. 612
  13. 613

    Table 2_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx حسب Tengxiang Zhao (20749475)

    منشور في 2025
    "…Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.…"
  14. 614

    Table 1_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx حسب Tengxiang Zhao (20749475)

    منشور في 2025
    "…Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.…"
  15. 615
  16. 616
  17. 617
  18. 618
  19. 619
  20. 620